Coloplast A/S
F:CBH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Coloplast A/S
F:CBH
|
DK |
|
G
|
Grupo Aeroportuario del Sureste SAB de CV
SWB:AEDA
|
MX |
|
P
|
Parsons Corp
XBER:59P
|
US |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
DE |
|
T
|
Tieling Newcity Investment Holding Group Ltd
SZSE:000809
|
CN |
|
Chiyoda Co Ltd
TSE:8185
|
JP |
|
Nordic American Tanker Ltd
NYSE:NAT
|
BM |
|
Camtek Ltd
F:CMZ
|
IL |
|
M
|
MEP Corporation PCL
SET:MEB
|
TH |
Coloplast A/S
Coloplast A/S makes medical devices for people with intimate and chronic care needs. Its main products help with ostomy care, continence care, wound and skin care, and urology. These are usually disposable products such as bags, catheters, and dressings that patients use every day or healthcare professionals use in treatment. The company sells mainly to hospitals, clinics, distributors, and patients who manage long-term conditions at home. Some products are prescribed by doctors or supported by nurses, which makes Coloplast part of the care path rather than a one-time equipment seller. It earns money by selling these devices and related supplies again and again as patients keep using them. What makes Coloplast different is that it focuses on sensitive, high-need areas of care where comfort, reliability, and ease of use matter a lot. Its business depends less on big surgical equipment and more on routine replacement products for long-lasting medical conditions, giving it a steady role in the healthcare supply chain.
Coloplast A/S makes medical devices for people with intimate and chronic care needs. Its main products help with ostomy care, continence care, wound and skin care, and urology. These are usually disposable products such as bags, catheters, and dressings that patients use every day or healthcare professionals use in treatment.
The company sells mainly to hospitals, clinics, distributors, and patients who manage long-term conditions at home. Some products are prescribed by doctors or supported by nurses, which makes Coloplast part of the care path rather than a one-time equipment seller. It earns money by selling these devices and related supplies again and again as patients keep using them.
What makes Coloplast different is that it focuses on sensitive, high-need areas of care where comfort, reliability, and ease of use matter a lot. Its business depends less on big surgical equipment and more on routine replacement products for long-lasting medical conditions, giving it a steady role in the healthcare supply chain.
Organic Growth: Coloplast reported 8% organic growth in Q1, with both Ostomy Care and Continence Care outgrowing the market.
EBIT Margin: EBIT margin before special items was 27%, slightly down from 28% last year, but in line with management expectations.
Kerecis Momentum: Kerecis delivered 32% growth and was included in the final US reimbursement policy for skin substitutes, though implementation was delayed by two months to April 2025.
Skin Care Divestment: The divestment of the Skin Care business will positively impact group EBIT margin by ~30 basis points but reduce reported revenue for the year by DKK 350 million (~1.5 percentage points).
Product Recalls: Interventional Urology growth was impacted by a voluntary product recall, but sales are resuming and management expects to recover most lost revenue in H2.
Guidance Maintained: Full-year guidance for 8–9% organic revenue growth and ~28% EBIT margin before special items was reaffirmed.
US and Emerging Markets: US delivered double-digit growth, while Emerging Markets were soft due to tough comparisons, with improvement expected later in the year.
Cash Flow & Profit: Free cash flow rose to DKK 1.9 billion (+11% YoY on adjusted basis), and adjusted net profit before special items increased 17%.
